Holen Sie sich die Stockscreener-App
3.97
0.25%
-0.010
Schlusskurs vom Vortag:
$3.98
Offen:
$4.08
24-Stunden-Volumen:
776.86K
Relative Volume:
0.63
Marktkapitalisierung:
$169.92M
Einnahmen:
$1.23M
Nettoeinkommen (Verlust:
$-28.62M
KGV:
-2.529
EPS:
-1.5698
Netto-Cashflow:
$-14.11M
1W Leistung:
+1.28%
1M Leistung:
+27.45%
6M Leistung:
+82.11%
1J Leistung:
+22.91%
1-Tages-Spanne:
$3.95
$4.15
1-Wochen-Bereich:
$3.79
$4.20
52-Wochen-Spanne:
$1.62
$5.055
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Firmenname
Nrx Pharmaceuticals Inc
Sektor
Branche
Telefon
484-254-6134
Adresse
1201 ORANGE STREET, WILMINGTON
Compare NRXP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
3.97 | 169.92M | 1.23M | -28.62M | -14.11M | -1.5698 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-04-02 | Eingeleitet | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Aktie (NRXP) Neueste Nachrichten
NRX Pharmaceuticals Inc (NRXPW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NRX Pharmaceuticals Inc (NRXPW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NRX Pharmaceuticals Inc (NRXP) Institutional Confidence - TradingKey
NRX Pharmaceuticals Inc (NRXPW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NRX Pharmaceuticals Inc (NRXP) Valuation: PE, PB & Fair Value Analysis - TradingKey
NRX Pharmaceuticals Inc (NRXP) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
NRX Pharmaceuticals Inc (NRXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NRX Pharmaceuticals Inc (NRXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NRX Pharmaceuticals Inc (NRXP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NRX Pharmaceuticals Inc (NRXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NRX Pharmaceuticals Inc (NRXPW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NRX Pharmaceuticals Inc (NRXPW) Valuation: PE, PB & Fair Value Analysis - TradingKey
NRX Pharmaceuticals Inc (NRXPW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NRX Pharmaceuticals Inc (NRXPW) Institutional Confidence - TradingKey
NRX Pharmaceuticals Inc (NRXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NRX Pharmaceuticals Inc (NRXP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NRX Pharmaceuticals Inc (NRXPW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NRX Pharmaceuticals Inc (NRXPW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NRXP Stock Price, Quote & Chart - ChartMill
NRXP News | NRX PHARMACEUTICALS INC (NASDAQ:NRXP) - ChartMill
NRx Pharmaceuticals, Inc. (NRXP) Latest Stock News & Headlines - Yahoo Finance
5 Hot Biotech Stocks Under $5 to Buy - Insider Monkey
NRx Pharmaceuticals (NRXP) Closes Underwritten Public Offering of Common Stock At $3.50 Per Share - Insider Monkey
symbol__ Stock Quote Price and Forecast - CNN
Study finds IV ketamine shows higher remission rates than esketamine - Investing.com UK
Study finds IV ketamine shows higher remission rates than esketamine By Investing.com - Investing.com South Africa
NRx Pharmaceuticals announces proposed public stock offering - MSN
NRx Pharmaceuticals notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. - Investing News Network
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. - The Manila Times
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by - GlobeNewswire
Depression study: IV ketamine patients remitted more than nasal esketamine - Stock Titan
NRx Pharmaceuticals Announces Underwriting Agreement and Public Offering of Common Stock - Minichart
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' Option - Investing News Network
NRx Pharmaceuticals closes $22.3M public offering - Investing.com UK
NRx Pharmaceuticals Announces $20 Million Public Stock Offering - TipRanks
NRx Pharmaceuticals closes $22.3M public offering By Investing.com - Investing.com India
NRX Pharmaceuticals Inc. announced the successful completion of its public offering of common stock, raising a total of $22.3 million. - Bitget
NRX Pharmaceuticals Closes $22.3 Million Stock Offering - marketscreener.com
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ Option - The Manila Times
NRx Pharmaceuticals Prices $3.50 Stock Offering to Raise ~$18.8 Million; BTIG Leads - TradingView
NRx Pharmaceuticals (NASDAQ: NRXP) closes $22.3M stock sale - Stock Titan
NRx Pharmaceuticals Closes $22.3 Million Public Offering to Support Growth and Development of CNS Therapeutics - Quiver Quantitative
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 - GlobeNewswire
Neuro stocks outpace broader markets as psychedelics, Axsome shine - BioWorld News
NRX Pharmaceuticals Prices Public Offering of 5.7 Million Shares - Moomoo
NRx Pharmaceuticals Shares Drop After $20M Public Offering Prices - Moomoo
NRx Pharmaceuticals Plans Underwritten Public Stock Offering - The Globe and Mail
NRx Pharmaceuticals (NASDAQ: NRXP) sells 5.7M shares at $3.50 - Stock Titan
NRXP: Lucid Capital Manages Successful Offering - GuruFocus
NRx Pharmaceuticals announces pricing of public offering of common stock - MSN
NRx Pharmaceuticals Prices $20 Million Public Stock Offering - citybiz
Finanzdaten der Nrx Pharmaceuticals Inc-Aktie (NRXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):